Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VALVET CARE CO., LTD. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner, OGUNBIYI, OLUWATOSIN A, and is located in a distinct art unit. OGUNBIYI, OLUWATOSIN A is the busiest examiner for the portfolio, with 1 pending office action.
The presence of a distinct art unit for the pending action shows a very focused prosecution effort. With only 1 pending office action in the entire portfolio, the company's current interaction with the patent office is limited to this single examiner. This means that OGUNBIYI, OLUWATOSIN A is responsible for the review of the company's entire active biotechnology patent matter. This centralized structure allows the company to concentrate its resources on a specific technical challenge while navigating the examination process with one primary point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611899 | GASTRIC ACID-STABLE PROBIOTIC FORMULATUION AND THE PREAPATION METHOD THEREOF | OGUNBIYI, OLUWATOSIN A | 62d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611899 | GASTRIC ACID-STABLE PROBIOTIC FORMULATUION AND THE PREAPATION METHOD THEREOF | OGUNBIYI, OLUWATOSIN A | 62d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18611899 | GASTRIC ACID-STABLE PROBIOTIC FORMULATUION AND THE PREAPATION METHOD THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103Other | Final Rejection | 62d | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial